At Boston Scientific, caring for human life is the common bond that connects our mission, business priorities and environmental, social and governance (ESG) strategy. As we grow to meet the increasing ...
Boston Scientific (BSX) is drawing fresh attention as investors weigh upbeat analyst commentary, steady demand across key ...
Boston Scientific BSX has solidified its footing as one of three major cardiac device makers and significantly improved its innovation and operational chops. We think the firm’s ability to emerge ...
BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition ...
Boston Scientific (NYSE: BSX) is scheduled to report its Q1 2023 results on Wednesday, April 26. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in ...
Here are six recent news updates on gastroenterology and endoscopy companies. Boston Scientific received FDA 510(k) clearance for its SpyGlass DS Direct Visualization System. The system is cleared for ...
Zacks Investment Research on MSN
If you invested $1000 in Boston Scientific 10 years ago, this is how much you'd have now
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and ...
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Boston Scientific agreed to acquire Remon Medical Technologies, an Israeli maker of wireless technology for communicating with implanted medical devices. The companies didn’t disclose financial terms; ...
Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded ...
Boston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over this ...
Boston Scientific (NYSE: BSX) is scheduled to report its Q1 2023 results on Wednesday, April 26. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback